Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent's COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate in the first of two Phase 1 studies to support its use for potential post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2, the virus that causes COVID-19, such as front-line health care workers and military personnel.

Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

Emergent Biosolutions (EBS) Down 14.7% Since Last Earnings Report: Can It Rebound?

Americold Realty

Could these stocks be winners regardless of which coronavirus vaccine comes out on top?

2 Pick-and-Shovel COVID Vaccine Stocks to Watch

Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.

Is Emergent BioSolutions (EBS) a Good Stock to Pick Now?

While profitability came in above estimates, the company missed big on the top line.

Why Emergent BioSolutions Slipped on Friday

Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance.

Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call Transcript

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Q3 Earnings Top Estimates

Emergent Biosolutions (EBS) closed the most recent trading day at $90.77, moving -0.55% from the previous trading session.

Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know

Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in their portfolio, and ~60% of total revenues are backed by US Government contract agreements.

Emergent BioSolutions: Deep Value Play With 33% Upside & Military Exposure

Is (EBS) Outperforming Other Medical Stocks This Year?

Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?

In the latest trading session, Emergent Biosolutions (EBS) closed at $99.55, marking a +1.86% move from the previous day.

Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Emergent Biosolutions (EBS)

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2020, recent business developments, revenue guidance for the fourth quarter of 2020, and financial outlook for full year 2020.

Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020

Blame it on Johnson & Johnson's pause of a late-stage study of its coronavirus vaccine candidate.

Why Emergent BioSciences Stock Is Falling Today

Cellectis SA

Thermo Fisher Scientific

Vertex Pharmaceuticals

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

Quest Diagnostics

Regeneron Pharmaceuticals

Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.

3 Stocks to Buy No Matter What Happens in November

GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with coronavirus disease (COVID-19). The INSIGHT-013 clinical study called “Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC),” is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study will evaluate the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, the virus that causes COVID-19. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent’s COVID-HIG, with a background therapy of remdesivir in all groups.

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year?

BeiGene

Horizon Pharma

Repligen

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes

Emergent BioSolutions has been struggling lately, but the selling pressure may be coming to an end soon.

Emergent BioSolutions Sees Hammer Chart Pattern: Time to Buy?

Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105.

Can Emergent Biosolutions Stock See Higher Levels?

Atlas Air Worldwide

Daqo New Energy

Etsy

Stamps.com

In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.

This September Could Be Different: 5 Stocks to Buy

Aspen Technology Inc

Dick's Sporting Goods

Dycom Industries

At Home Group

Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most

News for Emergent BioSolutions Stock (EBS)